Cotellic (Cobimetinib Fumarate) Patent Expiration, LOE Window & CMS Spending
Cotellic (Cobimetinib Fumarate) by Roche / Genentech: FDA Orange Book core substance LOE 2036-12-30, 0 AB generics, $10.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Roche / Genentech |
| FDA Application & Pathway | N206192 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2036-12-30 |
| Last Listed Patent or Exclusivity Date | 2036-12-30 |
| Orange Book Patents (*PED Extensions) | 13 patents (6 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $10.5M |
| 2024 Medicare Part D Spend | $8.2M |
| 2024 Medicaid Spend | $2.4M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.